Research analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a report released on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.
Separately, Roth Mkm cut their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.
Read Our Latest Report on APVO
Aptevo Therapeutics Stock Down 22.1 %
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.26. Sell-side analysts forecast that Aptevo Therapeutics will post -2.97 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Articles
- Five stocks we like better than Aptevo Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Dividend Payout Ratio Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.